Literature DB >> 27934877

Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications.

Ruri Saito1, Hiroyuki Abe2, Akiko Kunita1, Hiroharu Yamashita3, Yasuyuki Seto3, Masashi Fukayama1,2.   

Abstract

Cancer cells use PD-L1 to evade antitumor immunity through interaction with programmed cell death protein 1 (PD-1) on T cells. Recent whole-genome sequence studies revealed frequent gene amplification of PD-L1 in Epstein-Barr virus-associated gastric cancer (EBVaGC). To investigate the significance of PD-L1 in cancer cells and their microenvironment in EBVaGC, we studied PD-L1 expression by analysis of the public database and immunohistochemistry with fluorescent in situ hybridization (FISH) of the PD-L1 gene. Analysis of the database from The Cancer Genome Atlas also disclosed high expression of PD-L1 in EBVaGC compared with other molecular subtypes of GC. Expression of PD-L1 was frequently detected in cancer cells of EBVaGC (33/96; 34%), with infiltration of PD-L1+ immune cells in its stroma (43/96; 45%). Both expression of PD-L1 in cancer cells and PD-L1+ immune cell infiltration in EBVaGC were significantly correlated with diffuse histology according to Lauren's classification and tumor invasion (pT1b or more). As a prognostic indicator, PD-L1 expression in cancer cells correlated with poor outcomes in both overall survival and disease-specific survival (P=0.0498, 0.007). PD-L1-positive cancers had dense infiltration of PD-L1+ immune cells as well as CD8+ and PD-1+ cells in EBVaGC. FISH analysis of representative samples of the tumor demonstrated gene amplification of PD-L1 in 11% of cases. PD-L1-amplified cells corresponded to PD-L1-positive cells showing high-intensity immunohistochemical staining among cancer cells showing weak or moderate intensities. Taken together, PD-L1 expression in cancer cells and their microenvironment may contribute to the progression of EBVaGC, and gene amplification occurs as clonal evolution during progression. This specific subtype of GC infected with EBV is potentially a good candidate for immunotherapy targeting of the PD-L1/PD-1 axis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27934877     DOI: 10.1038/modpathol.2016.202

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  65 in total

1.  Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.

Authors:  Joo Yeon Kim; Woo Gyeong Kim; Chae Hwa Kwon; Do Youn Park
Journal:  Gastric Cancer       Date:  2019-05-31       Impact factor: 7.370

2.  Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma.

Authors:  O Jimenez; S Colli; M Garcia Lombardi; M V Preciado; E De Matteo; P Chabay
Journal:  Cancer Immunol Immunother       Date:  2020-11-12       Impact factor: 6.968

3.  CD47 expression in Epstein-Barr virus-associated gastric carcinoma: coexistence with tumor immunity lowering the ratio of CD8+/Foxp3+ T cells.

Authors:  Hiroyuki Abe; Ruri Saito; Takashi Ichimura; Akiko Iwasaki; Sho Yamazawa; Aya Shinozaki-Ushiku; Teppei Morikawa; Tetsuo Ushiku; Hiroharu Yamashita; Yasuyuki Seto; Masashi Fukayama
Journal:  Virchows Arch       Date:  2018-03-13       Impact factor: 4.064

4.  In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action.

Authors:  Derek J Blevins; Ronan Hanley; Trevor Bolduc; David A Powell; Michael Gignac; Kayleigh Walker; Mark D Carr; Fraser Hof; Jeremy E Wulff
Journal:  ACS Med Chem Lett       Date:  2019-07-02       Impact factor: 4.345

5.  Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.

Authors:  Raghav Sundar; Aditi Qamra; Angie Lay Keng Tan; Shenli Zhang; Cedric Chuan Young Ng; Bin Tean Teh; Jeeyun Lee; Kyoung-Mee Kim; Patrick Tan
Journal:  Gastric Cancer       Date:  2018-06-18       Impact factor: 7.370

Review 6.  CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway.

Authors:  Pablo Penaloza-MacMaster
Journal:  Immunology       Date:  2017-04-25       Impact factor: 7.397

7.  Multiparametric immune profiling in HPV- oral squamous cell cancer.

Authors:  Zipei Feng; Daniel Bethmann; Matthias Kappler; Carmen Ballesteros-Merino; Alexander Eckert; R Bryan Bell; Allen Cheng; Tuan Bui; Rom Leidner; Walter J Urba; Kent Johnson; Clifford Hoyt; Carlo B Bifulco; Juergen Bukur; Claudia Wickenhauser; Barbara Seliger; Bernard A Fox
Journal:  JCI Insight       Date:  2017-07-20

8.  Epstein-Barr virus-positive plasmacytoma in immunocompetent patients: a diagnostic dilemma.

Authors:  Lu He; Zhiwen Li; Xiangshan Fan; Qianyun Shi; Hongyan Wu; Jieyu Chen
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

9.  New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.

Authors:  Irene Gullo; Patrícia Oliveira; Maria Athelogou; Gilza Gonçalves; Marta L Pinto; Joana Carvalho; Ana Valente; Hugo Pinheiro; Sara Andrade; Gabriela M Almeida; Ralf Huss; Kakoli Das; Patrick Tan; José C Machado; Carla Oliveira; Fátima Carneiro
Journal:  Gastric Cancer       Date:  2018-05-19       Impact factor: 7.370

Review 10.  Outlooks on Epstein-Barr virus associated gastric cancer.

Authors:  Madiha Naseem; Afsaneh Barzi; Christine Brezden-Masley; Alberto Puccini; Martin D Berger; Ryuma Tokunaga; Francesca Battaglin; Shivani Soni; Michelle McSkane; Wu Zhang; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2018-03-31       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.